Protein Degradation Assay – PROTAC Screening
Protein degraders comprise a class of molecules that induce protein degradation of a specific disease-causing protein by the cell’s ubiquitin-proteasome pathway. In the past few years, various molecule classes have evolved, including PROTACs (Proteolysis-targeting chimeras), molecular glue, selective receptor degraders, and cerebron-binding molecules, to name a few.
All compounds to be screened in protein degradation assays have in common a drug discovery approach that is different from the classic inhibition of the function of a target. The discovery of new molecules facilitating targeted protein degradation requires a set of assays to investigate the binding of a drug to target, the structure of the drug-target complex, and the degradation of the target from the cell.
Reaction Biology works with Medinoah to accelerate the discovery of new drugs facilitating targeted protein degradation. Medinoah is a medicinal chemistry provider with expertise in drug synthesis and structural optimization and is one of the earliest CROs entering the PROTAC field. Together we offer the Rethinking PROTAC platform – a one-stop shop for the integrated discovery of new PROTAC molecules.
